256 related articles for article (PubMed ID: 32092358)
1. Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye.
Raibagkar P
Immunol Lett; 2020 May; 221():72-74. PubMed ID: 32092358
[No Abstract] [Full Text] [Related]
2. Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors.
Xiao Y; Zeng L; Shen Q; Zhou Z; Mao Z; Wang Q; Zhang X; Li Y; Yao W
J Immunol Res; 2020; 2020():2640273. PubMed ID: 32832568
[TBL] [Abstract][Full Text] [Related]
3. How to select cancer patients for immunotherapy.
Pfeiffer P; Qvortrup C; Hansen KH
EBioMedicine; 2021 Jan; 63():103184. PubMed ID: 33418504
[No Abstract] [Full Text] [Related]
4. Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer.
Jin KT; Wang SB; Ying XJ; Lan HR; Lv JQ; Zhang LH; Motallebnezhad M; Mou XZ
Immunol Lett; 2020 May; 221():61-71. PubMed ID: 32097671
[TBL] [Abstract][Full Text] [Related]
5. Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.
Xu Y; Fu Y; Zhu B; Wang J; Zhang B
Front Immunol; 2020; 11():2023. PubMed ID: 33123120
[TBL] [Abstract][Full Text] [Related]
6. A case of Schönlein-Henoch purpura induced by immune checkpoint inhibitor in a patient with metastatic melanoma.
Belkaid S; Berger M; Nouvier M; Picard C; Dalle S
Eur J Cancer; 2020 Nov; 139():169-172. PubMed ID: 32992155
[No Abstract] [Full Text] [Related]
7. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
Yao S; Li X; Nong J; Zhang Y
Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics modulates the complexity of the response to Immune Checkpoint Blockade.
Barragan I
EBioMedicine; 2020 Oct; 60():103005. PubMed ID: 32987318
[No Abstract] [Full Text] [Related]
9. Onset of subacute cutaneous lupus erythematosus after the initiation of immune checkpoint inhibitor therapy of cancer.
Gambichler T; Doerler M; Scheel CH
Lupus; 2021 Mar; 30(3):531-533. PubMed ID: 33407044
[No Abstract] [Full Text] [Related]
10. [New AMM: Nivolumab for advanced oesophageal squamous cell carcinomia after first line of chemotherapy].
Reich M; Coutzac C
Bull Cancer; 2021 Mar; 108(3):228-229. PubMed ID: 33531154
[No Abstract] [Full Text] [Related]
11. Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors.
Joshi M; Ansell SM
J Immunol Res; 2020; 2020():8820377. PubMed ID: 33294467
[TBL] [Abstract][Full Text] [Related]
12. Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer.
Dermime S; Merhi M; Merghoub T
Front Immunol; 2021; 12():781872. PubMed ID: 34745152
[No Abstract] [Full Text] [Related]
13. Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis.
Duchemann B; Pluvy J; Crestani B; Zalcman G; Nunes H
Eur J Cancer; 2021 Mar; 145():179-182. PubMed ID: 33486441
[No Abstract] [Full Text] [Related]
14. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
15. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.
Galluzzi L; Humeau J; Buqué A; Zitvogel L; Kroemer G
Nat Rev Clin Oncol; 2020 Dec; 17(12):725-741. PubMed ID: 32760014
[TBL] [Abstract][Full Text] [Related]
16. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors.
Fernandes S; Varlamov EV; McCartney S; Fleseriu M
Endocrinol Metab Clin North Am; 2020 Sep; 49(3):387-399. PubMed ID: 32741478
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitors - The Need for Innovation.
Johnson PC; Gainor JF; Sullivan RJ; Longo DL; Chabner B
N Engl J Med; 2023 Apr; 388(16):1529-1532. PubMed ID: 37075146
[No Abstract] [Full Text] [Related]
18. TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy.
Qiu H; Shao Z; Wen X; Jiang J; Ma Q; Wang Y; Huang L; Ding X; Zhang L
Front Immunol; 2021; 12():716710. PubMed ID: 34539652
[TBL] [Abstract][Full Text] [Related]
19. Immune-related cutaneous adverse events: A new opportunity for allergists and clinical immunologists.
Leung DYM
Ann Allergy Asthma Immunol; 2021 Jun; 126(6):607. PubMed ID: 34049668
[No Abstract] [Full Text] [Related]
20. Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy.
Yan C; Richmond A
Mol Cancer; 2021 Nov; 20(1):146. PubMed ID: 34758832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
